Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program
Abstract Background Staphylococcus aureus is among the most common human pathogens, with therapy complicated by the epidemic spread of methicillin-resistant Staphylococcus aureus (MRSA). Methods The SENTRY Antimicrobial Surveillance Program evaluated the in vitro activity of >20 antimicrobials ag...
Uloženo v:
| Vydáno v: | Open forum infectious diseases Ročník 6; číslo Supplement_1; s. S47 - S53 |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
US
Oxford University Press
01.03.2019
|
| Témata: | |
| ISSN: | 2328-8957, 2328-8957 |
| On-line přístup: | Získat plný text |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Abstract
Background
Staphylococcus aureus is among the most common human pathogens, with therapy complicated by the epidemic spread of methicillin-resistant Staphylococcus aureus (MRSA).
Methods
The SENTRY Antimicrobial Surveillance Program evaluated the in vitro activity of >20 antimicrobials against 191 460 clinical S. aureus isolates collected from 427 centers in 45 countries from 1997 to 2016. Each center contributed isolates and clinical data for consecutive episodes of bacteremia, pneumonia in hospitalized patients, urinary tract infection, and skin and skin structure infection.
Results
Overall, 191 460 S. aureus isolates were collected, of which 77 146 (40.3%) were MRSA, varying geographically from 26.8% MRSA in Europe to 47.0% in North America. The highest percentage of MRSA was in nosocomial isolates from patients aged >80 years. Overall, MRSA occurrences increased from 33.1% in 1997–2000 to a high of 44.2% in 2005–2008, then declined to 42.3% and 39.0% in 2009–2012 and 2013–2016, respectively. S. aureus bacteremia had a similar trend, with nosocomial and community-onset MRSA rates peaking in 2005–2008 and then declining. Vancomycin activity against S. aureus remained stable (minimum inhibitory concentration [MIC]90 of 1 mg/L and 100% susceptibility in 2016; no increase over time in isolates with a vancomycin MIC >1 mg/L). Several agents introduced during the surveillance period exhibited in vitro potency against MRSA.
Conclusions
In a large global surveillance program, the rise of MRSA as a proportion of all S. aureus peaked a decade ago and has declined since, consistent with some regional surveillance program reports. Vancomycin maintained high activity against S. aureus, and several newer agents exhibited excellent in vitro potencies. |
|---|---|
| AbstractList | is among the most common human pathogens, with therapy complicated by the epidemic spread of methicillin-resistant
(MRSA).
The SENTRY Antimicrobial Surveillance Program evaluated the in vitro activity of >20 antimicrobials against 191 460 clinical
isolates collected from 427 centers in 45 countries from 1997 to 2016. Each center contributed isolates and clinical data for consecutive episodes of bacteremia, pneumonia in hospitalized patients, urinary tract infection, and skin and skin structure infection.
Overall, 191 460
isolates were collected, of which 77 146 (40.3%) were MRSA, varying geographically from 26.8% MRSA in Europe to 47.0% in North America. The highest percentage of MRSA was in nosocomial isolates from patients aged >80 years. Overall, MRSA occurrences increased from 33.1% in 1997-2000 to a high of 44.2% in 2005-2008, then declined to 42.3% and 39.0% in 2009-2012 and 2013-2016, respectively.
bacteremia had a similar trend, with nosocomial and community-onset MRSA rates peaking in 2005-2008 and then declining. Vancomycin activity against
remained stable (minimum inhibitory concentration [MIC]
of 1 mg/L and 100% susceptibility in 2016; no increase over time in isolates with a vancomycin MIC >1 mg/L). Several agents introduced during the surveillance period exhibited in vitro potency against MRSA.
In a large global surveillance program, the rise of MRSA as a proportion of all
peaked a decade ago and has declined since, consistent with some regional surveillance program reports. Vancomycin maintained high activity against
, and several newer agents exhibited excellent in vitro potencies. Abstract Background Staphylococcus aureus is among the most common human pathogens, with therapy complicated by the epidemic spread of methicillin-resistant Staphylococcus aureus (MRSA). Methods The SENTRY Antimicrobial Surveillance Program evaluated the in vitro activity of >20 antimicrobials against 191 460 clinical S. aureus isolates collected from 427 centers in 45 countries from 1997 to 2016. Each center contributed isolates and clinical data for consecutive episodes of bacteremia, pneumonia in hospitalized patients, urinary tract infection, and skin and skin structure infection. Results Overall, 191 460 S. aureus isolates were collected, of which 77 146 (40.3%) were MRSA, varying geographically from 26.8% MRSA in Europe to 47.0% in North America. The highest percentage of MRSA was in nosocomial isolates from patients aged >80 years. Overall, MRSA occurrences increased from 33.1% in 1997–2000 to a high of 44.2% in 2005–2008, then declined to 42.3% and 39.0% in 2009–2012 and 2013–2016, respectively. S. aureus bacteremia had a similar trend, with nosocomial and community-onset MRSA rates peaking in 2005–2008 and then declining. Vancomycin activity against S. aureus remained stable (minimum inhibitory concentration [MIC]90 of 1 mg/L and 100% susceptibility in 2016; no increase over time in isolates with a vancomycin MIC >1 mg/L). Several agents introduced during the surveillance period exhibited in vitro potency against MRSA. Conclusions In a large global surveillance program, the rise of MRSA as a proportion of all S. aureus peaked a decade ago and has declined since, consistent with some regional surveillance program reports. Vancomycin maintained high activity against S. aureus, and several newer agents exhibited excellent in vitro potencies. Background Staphylococcus aureus is among the most common human pathogens, with therapy complicated by the epidemic spread of methicillin-resistant Staphylococcus aureus (MRSA). Methods The SENTRY Antimicrobial Surveillance Program evaluated the in vitro activity of >20 antimicrobials against 191 460 clinical S. aureus isolates collected from 427 centers in 45 countries from 1997 to 2016. Each center contributed isolates and clinical data for consecutive episodes of bacteremia, pneumonia in hospitalized patients, urinary tract infection, and skin and skin structure infection. Results Overall, 191 460 S. aureus isolates were collected, of which 77 146 (40.3%) were MRSA, varying geographically from 26.8% MRSA in Europe to 47.0% in North America. The highest percentage of MRSA was in nosocomial isolates from patients aged >80 years. Overall, MRSA occurrences increased from 33.1% in 1997–2000 to a high of 44.2% in 2005–2008, then declined to 42.3% and 39.0% in 2009–2012 and 2013–2016, respectively. S. aureus bacteremia had a similar trend, with nosocomial and community-onset MRSA rates peaking in 2005–2008 and then declining. Vancomycin activity against S. aureus remained stable (minimum inhibitory concentration [MIC]90 of 1 mg/L and 100% susceptibility in 2016; no increase over time in isolates with a vancomycin MIC >1 mg/L). Several agents introduced during the surveillance period exhibited in vitro potency against MRSA. Conclusions In a large global surveillance program, the rise of MRSA as a proportion of all S. aureus peaked a decade ago and has declined since, consistent with some regional surveillance program reports. Vancomycin maintained high activity against S. aureus, and several newer agents exhibited excellent in vitro potencies. Staphylococcus aureus is among the most common human pathogens, with therapy complicated by the epidemic spread of methicillin-resistant Staphylococcus aureus (MRSA).BackgroundStaphylococcus aureus is among the most common human pathogens, with therapy complicated by the epidemic spread of methicillin-resistant Staphylococcus aureus (MRSA).The SENTRY Antimicrobial Surveillance Program evaluated the in vitro activity of >20 antimicrobials against 191 460 clinical S. aureus isolates collected from 427 centers in 45 countries from 1997 to 2016. Each center contributed isolates and clinical data for consecutive episodes of bacteremia, pneumonia in hospitalized patients, urinary tract infection, and skin and skin structure infection.MethodsThe SENTRY Antimicrobial Surveillance Program evaluated the in vitro activity of >20 antimicrobials against 191 460 clinical S. aureus isolates collected from 427 centers in 45 countries from 1997 to 2016. Each center contributed isolates and clinical data for consecutive episodes of bacteremia, pneumonia in hospitalized patients, urinary tract infection, and skin and skin structure infection.Overall, 191 460 S. aureus isolates were collected, of which 77 146 (40.3%) were MRSA, varying geographically from 26.8% MRSA in Europe to 47.0% in North America. The highest percentage of MRSA was in nosocomial isolates from patients aged >80 years. Overall, MRSA occurrences increased from 33.1% in 1997-2000 to a high of 44.2% in 2005-2008, then declined to 42.3% and 39.0% in 2009-2012 and 2013-2016, respectively. S. aureus bacteremia had a similar trend, with nosocomial and community-onset MRSA rates peaking in 2005-2008 and then declining. Vancomycin activity against S. aureus remained stable (minimum inhibitory concentration [MIC]90 of 1 mg/L and 100% susceptibility in 2016; no increase over time in isolates with a vancomycin MIC >1 mg/L). Several agents introduced during the surveillance period exhibited in vitro potency against MRSA.ResultsOverall, 191 460 S. aureus isolates were collected, of which 77 146 (40.3%) were MRSA, varying geographically from 26.8% MRSA in Europe to 47.0% in North America. The highest percentage of MRSA was in nosocomial isolates from patients aged >80 years. Overall, MRSA occurrences increased from 33.1% in 1997-2000 to a high of 44.2% in 2005-2008, then declined to 42.3% and 39.0% in 2009-2012 and 2013-2016, respectively. S. aureus bacteremia had a similar trend, with nosocomial and community-onset MRSA rates peaking in 2005-2008 and then declining. Vancomycin activity against S. aureus remained stable (minimum inhibitory concentration [MIC]90 of 1 mg/L and 100% susceptibility in 2016; no increase over time in isolates with a vancomycin MIC >1 mg/L). Several agents introduced during the surveillance period exhibited in vitro potency against MRSA.In a large global surveillance program, the rise of MRSA as a proportion of all S. aureus peaked a decade ago and has declined since, consistent with some regional surveillance program reports. Vancomycin maintained high activity against S. aureus, and several newer agents exhibited excellent in vitro potencies.ConclusionsIn a large global surveillance program, the rise of MRSA as a proportion of all S. aureus peaked a decade ago and has declined since, consistent with some regional surveillance program reports. Vancomycin maintained high activity against S. aureus, and several newer agents exhibited excellent in vitro potencies. |
| Author | Diekema, Daniel J Pfaller, Michael A Zervos, Marcos Shortridge, Dee Jones, Ronald N |
| AuthorAffiliation | 2 JMI Laboratories, North Liberty, Iowa 1 University of Iowa Carver College of Medicine, Iowa City, Iowa 3 Henry Ford Hospital, Detroit, Michigan 4 Wayne State University School of Medicine, Detroit, Michigan |
| AuthorAffiliation_xml | – name: 1 University of Iowa Carver College of Medicine, Iowa City, Iowa – name: 2 JMI Laboratories, North Liberty, Iowa – name: 3 Henry Ford Hospital, Detroit, Michigan – name: 4 Wayne State University School of Medicine, Detroit, Michigan |
| Author_xml | – sequence: 1 givenname: Daniel J surname: Diekema fullname: Diekema, Daniel J email: daniel-diekema@uiowa.edu organization: University of Iowa Carver College of Medicine, Iowa City, Iowa – sequence: 2 givenname: Michael A surname: Pfaller fullname: Pfaller, Michael A organization: University of Iowa Carver College of Medicine, Iowa City, Iowa – sequence: 3 givenname: Dee surname: Shortridge fullname: Shortridge, Dee organization: JMI Laboratories, North Liberty, Iowa – sequence: 4 givenname: Marcos surname: Zervos fullname: Zervos, Marcos organization: Henry Ford Hospital, Detroit, Michigan – sequence: 5 givenname: Ronald N surname: Jones fullname: Jones, Ronald N organization: JMI Laboratories, North Liberty, Iowa |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30895214$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9klFrFDEQx4NUbK198l0CggjlbLK72ey-CEdprVC0eOdDn0KSndyl7CbbJFu5Z7-4Oa6VWkUCMwPzmz8zk3mJ9px3gNBrSj5Q0pYn3tgum03ByTN0UJRFM2taxvcexfvoKMYbQgilhBHevkD7JcmJglYH6OfyB7i0mV2DDHgZwHURW4fnLtnB6uCVlT1eTFHDmKyyvU0WIp4P3q3wIslxvem99lpPEcspQHbnwQ84rQEvzr4sv13_JRXuwPa9dBrwVfCrIIdX6LmRfYSje3-Ivp-fLU8vZpdfP30-nV_ONCN1yhZU02iqmtJQRih0pTGG85bVWvOyq02ngDNjGpDS8LYwrKtalZ_RSitVHqKPO91xUgN0Og8eZC_GYAcZNsJLK_7MOLsWK38n6oq2TVtlgff3AsHfThCTGGzezHYa8FMUBc1bZTVhPKNvn6A3fgoujydKyklbcVaQTL153NHvVh7-JwN0B-T9xRjACG2TTNZvG7S9oERsz0Bsz0DsziDXHD-peZD9N_1uR_tp_C_4C4o2x0M |
| CitedBy_id | crossref_primary_10_1097_FTD_0000000000000910 crossref_primary_10_1093_ofid_ofz554 crossref_primary_10_1016_j_sajb_2025_08_032 crossref_primary_10_1001_jamainternmed_2020_0555 crossref_primary_10_1016_j_jinf_2025_106462 crossref_primary_10_1007_s13312_023_2695_6 crossref_primary_10_1016_j_cmi_2019_10_029 crossref_primary_10_1016_j_jiac_2019_10_017 crossref_primary_10_1093_jac_dkaf218 crossref_primary_10_1007_s11739_020_02302_6 crossref_primary_10_1038_s41579_024_01054_w crossref_primary_10_2217_fmb_2022_0232 crossref_primary_10_3389_fpubh_2025_1607801 crossref_primary_10_1128_JCM_01195_19 crossref_primary_10_2217_fmb_2022_0074 crossref_primary_10_3390_antibiotics13020123 crossref_primary_10_2217_fmb_2022_0230 crossref_primary_10_3390_pathogens13010025 crossref_primary_10_1016_j_jgar_2021_04_020 crossref_primary_10_1016_j_jacc_2021_02_014 crossref_primary_10_1016_j_ijantimicag_2021_106503 crossref_primary_10_1016_j_ijid_2022_06_026 crossref_primary_10_3390_jpm12020163 crossref_primary_10_1016_j_jgar_2023_05_002 crossref_primary_10_1155_2022_1835603 crossref_primary_10_1002_cbdv_202100788 crossref_primary_10_1001_jamadermatol_2024_3360 crossref_primary_10_1155_2022_6828538 crossref_primary_10_1016_j_artmed_2021_102216 crossref_primary_10_1128_aac_01196_22 crossref_primary_10_3390_antibiotics13111023 crossref_primary_10_1016_j_jhin_2021_03_024 crossref_primary_10_1093_jac_dkae230 crossref_primary_10_3389_fmed_2022_901980 crossref_primary_10_3390_pathogens12121401 crossref_primary_10_1016_j_puhe_2021_07_046 crossref_primary_10_1016_j_micpath_2022_105743 crossref_primary_10_15789_2220_7619_NAF_17784 crossref_primary_10_1155_ijm_4558662 crossref_primary_10_1016_j_ijid_2022_02_002 crossref_primary_10_3390_antibiotics13090866 crossref_primary_10_1080_07853890_2022_2085881 crossref_primary_10_1016_j_jgar_2022_03_010 crossref_primary_10_1093_jac_dkz284 crossref_primary_10_3390_microorganisms11102575 crossref_primary_10_1093_jacamr_dlab177 crossref_primary_10_1128_AAC_01776_19 crossref_primary_10_1093_jacamr_dlae152 crossref_primary_10_1016_j_cmi_2024_07_018 crossref_primary_10_1016_j_ijantimicag_2024_107180 crossref_primary_10_1001_jamaophthalmol_2020_0155 crossref_primary_10_3389_fmicb_2025_1569242 crossref_primary_10_1016_j_cmi_2019_12_023 crossref_primary_10_1093_jpids_piaa136 crossref_primary_10_2147_IDR_S375206 crossref_primary_10_1016_j_jgar_2020_09_027 crossref_primary_10_1021_jacs_4c05057 crossref_primary_10_1016_j_drudis_2020_10_011 crossref_primary_10_1016_j_cmi_2019_10_031 crossref_primary_10_1128_spectrum_03815_23 crossref_primary_10_1080_1120009X_2023_2259673 crossref_primary_10_5582_bst_2021_01342 crossref_primary_10_1016_j_athoracsur_2020_10_029 crossref_primary_10_1128_AAC_01082_20 crossref_primary_10_1021_acsami_5c09975 crossref_primary_10_1128_jcm_00366_23 crossref_primary_10_1093_cid_ciaa475 crossref_primary_10_1097_INF_0000000000004932 crossref_primary_10_1177_00185787231196435 crossref_primary_10_1007_s10123_022_00249_6 crossref_primary_10_1016_j_epidem_2025_100848 crossref_primary_10_3390_antibiotics12081237 crossref_primary_10_1177_87551225231172349 crossref_primary_10_3390_microorganisms11061369 crossref_primary_10_1128_AAC_00355_19 crossref_primary_10_1128_spectrum_00608_24 crossref_primary_10_1007_s12104_023_10151_5 crossref_primary_10_1093_cid_ciaa1354 crossref_primary_10_1093_jac_dkac428 crossref_primary_10_2147_IDR_S340623 crossref_primary_10_1016_j_ijantimicag_2021_106310 crossref_primary_10_1128_AAC_02132_20 crossref_primary_10_1016_j_curtheres_2022_100687 crossref_primary_10_3390_antibiotics13010092 crossref_primary_10_3390_pharmaceutics14040805 crossref_primary_10_1128_spectrum_03623_22 crossref_primary_10_3390_antibiotics12091397 crossref_primary_10_1093_ofid_ofac090 crossref_primary_10_3390_antibiotics12030557 crossref_primary_10_1128_JCM_00239_21 crossref_primary_10_1186_s13756_021_00997_6 crossref_primary_10_1017_ice_2025_58 crossref_primary_10_3390_antibiotics12050900 crossref_primary_10_21303_2504_5695_2021_001925 crossref_primary_10_1093_cid_ciad571 crossref_primary_10_1097_ICO_0000000000002884 crossref_primary_10_1007_s40267_021_00888_1 crossref_primary_10_1128_aac_01402_24 crossref_primary_10_1128_spectrum_00869_24 crossref_primary_10_3390_microorganisms11051332 crossref_primary_10_3390_ph17070933 crossref_primary_10_1186_s12866_020_01881_w crossref_primary_10_1093_jac_dkab048 crossref_primary_10_2147_IDR_S318005 crossref_primary_10_3390_pathogens12050703 crossref_primary_10_1080_14728214_2019_1677607 crossref_primary_10_1002_sim_70160 crossref_primary_10_1007_s00253_020_10853_z crossref_primary_10_3390_molecules24244581 crossref_primary_10_1186_s12879_023_08471_x crossref_primary_10_1007_s10096_024_04919_3 crossref_primary_10_1128_msphere_00126_24 crossref_primary_10_1016_j_ajem_2024_10_040 crossref_primary_10_3389_fpubh_2023_1124930 crossref_primary_10_1016_j_lmd_2025_100088 crossref_primary_10_1093_ajhp_zxaa036 crossref_primary_10_1016_j_jiac_2021_11_019 crossref_primary_10_1128_AAC_00967_21 crossref_primary_10_1007_s10238_023_01206_x crossref_primary_10_1128_aac_00320_25 crossref_primary_10_1016_j_ijantimicag_2022_106538 crossref_primary_10_1093_cid_ciad560 crossref_primary_10_1128_spectrum_02749_24 crossref_primary_10_1016_j_diagmicrobio_2019_114977 crossref_primary_10_2147_IDR_S437920 crossref_primary_10_2147_IDR_S302416 crossref_primary_10_3390_antibiotics8040202 crossref_primary_10_1016_j_emcon_2025_100514 crossref_primary_10_1016_j_urology_2021_10_009 crossref_primary_10_3390_pr7120964 crossref_primary_10_13005_bpj_2062 crossref_primary_10_1007_s40121_022_00712_x crossref_primary_10_1093_jtm_taz036 crossref_primary_10_1007_s40123_021_00449_9 crossref_primary_10_1016_j_idc_2020_10_003 crossref_primary_10_3390_antibiotics12030591 crossref_primary_10_3390_microorganisms11030567 crossref_primary_10_1016_j_diagmicrobio_2020_115054 crossref_primary_10_1007_s42770_021_00566_4 crossref_primary_10_1080_17435889_2025_2500905 crossref_primary_10_1016_j_pharma_2022_12_007 crossref_primary_10_1097_INF_0000000000003030 crossref_primary_10_1128_MRA_00730_20 crossref_primary_10_1155_2020_1721936 crossref_primary_10_1186_s12879_025_10659_2 crossref_primary_10_1016_j_idc_2020_06_010 crossref_primary_10_1093_jac_dkad202 crossref_primary_10_1093_jtm_taaa242 crossref_primary_10_1017_ice_2021_350 crossref_primary_10_1007_s15010_023_02036_5 crossref_primary_10_1080_17460913_2024_2342150 crossref_primary_10_1111_jebm_12644 crossref_primary_10_1128_spectrum_00486_24 crossref_primary_10_22207_JPAM_18_3_36 |
| Cites_doi | 10.3201/eid0501.990102 10.2807/ese.16.11.19819-en 10.1016/j.diagmicrobio.2018.01.029 10.1056/NEJM199808203390806 10.1128/JCM.02187-13 10.1128/AAC.01043-17 10.1086/668770 10.3201/eid1510.080877 10.1001/jama.2010.1125 10.1128/JCM.03109-15 10.1128/JCM.01160-17 10.1056/NEJMoa1007474 10.1017/ice.2016.174 10.1086/675283 10.1093/jac/dkt317 10.1089/mdr.2000.6.213 10.1001/jama.2009.153 10.1016/j.ijantimicag.2018.04.003 10.1016/j.cmi.2017.06.017 10.1086/320184 10.1128/AAC.00113-08 10.1093/jac/dkr561 10.1001/jama.2010.1115 10.1016/j.amjmed.2016.01.048 10.1001/jama.298.15.1763 10.1080/23744235.2017.1405276 10.1038/nrmicro2200 10.1136/jcp.14.4.385 10.1093/cid/ciq146 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2019 The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2019 – notice: The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | TOX AAYXX CITATION NPM 3V. 7X7 7XB 8C1 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1093/ofid/ofy270 |
| DatabaseName | Oxford Journals Open Access Collection CrossRef PubMed ProQuest Central (Corporate) ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Public Health Database Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | PubMed Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: TOX name: Oxford Journals Open Access Collection url: https://academic.oup.com/journals/ sourceTypes: Publisher – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Global Surveillance of Antimicrobial Resistance: 20 Years of Experience with the SENTRY Program |
| EISSN | 2328-8957 |
| EndPage | S53 |
| ExternalDocumentID | PMC6419894 30895214 10_1093_ofid_ofy270 10.1093/ofid/ofy270 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: bioMeriuex, Inc. – fundername: ; |
| GroupedDBID | 0R~ 53G 5VS AAFWJ AAMVS AAPPN AAPXW AAVAP ABDBF ABPTD ABXVV ACGFS ADBBV ADHZD ADPDF ADRAZ AENZO AFPKN AFULF ALMA_UNASSIGNED_HOLDINGS ALUQC AOIJS BAWUL BAYMD BCNDV BTTYL CIDKT DIK EBS EJD GROUPED_DOAJ H13 HYE IAO KQ8 KSI M48 M~E O9- OAWHX OJQWA OK1 OVD OVEED PEELM ROL ROX RPM TEORI TJX TOX 7X7 8C1 8FI 8FJ AAYXX ABEJV ABGNP ABUWG ACUHS AFFHD AFKRA AMNDL BENPR CCPQU CITATION FYUFA HMCUK IHR ITC PHGZM PHGZT PIMPY PJZUB PPXIY UKHRP NPM 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c506t-c5eb88c1b83f1501ed3fff77956cc73d6fdbe75ff8eaaf792f5d49b9b9fcbcbb3 |
| IEDL.DBID | 8C1 |
| ISICitedReferencesCount | 172 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000510176800006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2328-8957 |
| IngestDate | Tue Nov 04 01:55:30 EST 2025 Sun Nov 09 10:52:20 EST 2025 Tue Oct 07 07:30:25 EDT 2025 Wed Feb 19 02:30:56 EST 2025 Tue Nov 18 22:15:54 EST 2025 Sat Nov 29 05:40:13 EST 2025 Wed Aug 28 03:19:25 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | Supplement_1 |
| Keywords | epidemiology antimicrobial resistance Staphylococcus aureus |
| Language | English |
| License | This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com http://creativecommons.org/licenses/by-nc-nd/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c506t-c5eb88c1b83f1501ed3fff77956cc73d6fdbe75ff8eaaf792f5d49b9b9fcbcbb3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://www.proquest.com/docview/3170947520?pq-origsite=%requestingapplication% |
| PMID | 30895214 |
| PQID | 3170947520 |
| PQPubID | 7089189 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6419894 proquest_miscellaneous_2195256057 proquest_journals_3170947520 pubmed_primary_30895214 crossref_citationtrail_10_1093_ofid_ofy270 crossref_primary_10_1093_ofid_ofy270 oup_primary_10_1093_ofid_ofy270 |
| PublicationCentury | 2000 |
| PublicationDate | 2019-03-01 |
| PublicationDateYYYYMMDD | 2019-03-01 |
| PublicationDate_xml | – month: 03 year: 2019 text: 2019-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | US |
| PublicationPlace_xml | – name: US – name: United States – name: Oxford |
| PublicationTitle | Open forum infectious diseases |
| PublicationTitleAlternate | Open Forum Infect Dis |
| PublicationYear | 2019 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| References | US Census Bureau (2020081004070240700_CIT0017) 2015 Klevens (2020081004070240700_CIT0002) 2007; 298 CLSI (2020081004070240700_CIT0020) 2018 Kanjilal (2020081004070240700_CIT0034) 2018; 56 Barber (2020081004070240700_CIT0006) 1961; 14 Kallen (2020081004070240700_CIT0023) 2010; 304 Pfaller (2020081004070240700_CIT0015) 2018; 91 Richter (2020081004070240700_CIT0035) 2016; 54 Weiner (2020081004070240700_CIT0005) 2016; 37 2020081004070240700_CIT0019 Crane (2020081004070240700_CIT0032) 2014; 69 Diekema (2020081004070240700_CIT0009) 2000; 6 Cheng (2020081004070240700_CIT0031) 2016; 129 Shah (2020081004070240700_CIT0036) Jain (2020081004070240700_CIT0026) 2011; 364 Jokinen (2020081004070240700_CIT0033) 2018; 50 Sievert (2020081004070240700_CIT0004) 2013; 34 Sader (2020081004070240700_CIT0016) 2017; 61 CLSI (2020081004070240700_CIT0018) 2018 Chambers (2020081004070240700_CIT0001) 2009; 7 Gagliotti (2020081004070240700_CIT0022) 2011; 16 Perencevich (2020081004070240700_CIT0028) 2010; 304 Andreatos (2020081004070240700_CIT0027) 2018; 52 Burton (2020081004070240700_CIT0021) 2009; 301 Chatterjee (2020081004070240700_CIT0007) 2013; 5 Limbago (2020081004070240700_CIT0012) 2014; 52 Johnson (2020081004070240700_CIT0025) 2012; 67 Diekema (2020081004070240700_CIT0011) 2014; 35 Diaz (2020081004070240700_CIT0014) 2018; 24 Lodise (2020081004070240700_CIT0013) 2008; 52 Diekema (2020081004070240700_CIT0024) 2001; 32 Rubin (2020081004070240700_CIT0003) 1999; 5 Chabot (2020081004070240700_CIT0030) 2015; 70 Liu (2020081004070240700_CIT0029) 2011; 52 Lowy (2020081004070240700_CIT0008) 1998; 339 Van De Griend (2020081004070240700_CIT0010) 2009; 15 31139676 - Open Forum Infect Dis. 2019 May 20;6(5):ofz202 |
| References_xml | – volume: 5 start-page: 9 year: 1999 ident: 2020081004070240700_CIT0003 article-title: The economic impact of Staphylococcus aureus infection in New York City hospitals publication-title: Emerg Infect Dis doi: 10.3201/eid0501.990102 – volume: 16 start-page: 19819 year: 2011 ident: 2020081004070240700_CIT0022 article-title: Escherichia coli and Staphylococcus aureus: bad news and good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS), 2002 to 2009 publication-title: Euro Surveill doi: 10.2807/ese.16.11.19819-en – volume: 91 start-page: 199 year: 2018 ident: 2020081004070240700_CIT0015 article-title: Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014 publication-title: Diagn Microbiol Infect Dis doi: 10.1016/j.diagmicrobio.2018.01.029 – ident: 2020081004070240700_CIT0036 article-title: Clinical outcomes with penicillin versus alternative beta-lactams in the treatment of penicillin-susceptible Staphylococcus aureus bacteremia publication-title: Pharmacotherapy – ident: 2020081004070240700_CIT0019 – volume: 339 start-page: 520 year: 1998 ident: 2020081004070240700_CIT0008 article-title: Staphylococcus aureus infections publication-title: N Engl J Med doi: 10.1056/NEJM199808203390806 – volume: 70 start-page: 3353 year: 2015 ident: 2020081004070240700_CIT0030 article-title: Reappearance and treatment of penicillin-susceptible Staphylococcus aureus in a tertiary medical centre publication-title: J Antimicrob Chemother – volume: 52 start-page: 998 year: 2014 ident: 2020081004070240700_CIT0012 article-title: Report of the 13th vancomycin-resistant Staphylococcus aureus isolate from the United States publication-title: J Clin Microbiol doi: 10.1128/JCM.02187-13 – volume-title: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard year: 2018 ident: 2020081004070240700_CIT0018 – volume: 5 start-page: 205 year: 2013 ident: 2020081004070240700_CIT0007 article-title: Improved understanding of factors driving methicillin-resistant Staphylococcus aureus epidemic waves publication-title: Clin Epidemiol – volume: 61 start-page: e01043 year: 2017 ident: 2020081004070240700_CIT0016 article-title: Antimicrobial susceptibility trends among Staphylococcus aureus from U. S. hospitals: results from 7 years of the ceftaroline (AWARE) surveillance program (2010–2016) publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01043-17 – volume: 34 start-page: 1 year: 2013 ident: 2020081004070240700_CIT0004 article-title: Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010 publication-title: Infect Control Hosp Epidemiol doi: 10.1086/668770 – volume: 15 start-page: 1582 year: 2009 ident: 2020081004070240700_CIT0010 article-title: Community-associated methicillin-resistant Staphylococcus aureus, Iowa, USA publication-title: Emerg Infect Dis doi: 10.3201/eid1510.080877 – volume: 304 start-page: 687 year: 2010 ident: 2020081004070240700_CIT0028 article-title: Decline in invasive MRSA infection: where to go from here? publication-title: JAMA doi: 10.1001/jama.2010.1125 – volume: 54 start-page: 812 year: 2016 ident: 2020081004070240700_CIT0035 article-title: Detection and prevalence of penicillin-susceptible Staphylococcus aureus in the United States in 2013 publication-title: J Clin Microbiol doi: 10.1128/JCM.03109-15 – year: 2015 ident: 2020081004070240700_CIT0017 – volume: 56 start-page: e01160 year: 2018 ident: 2020081004070240700_CIT0034 article-title: Trends in antibiotic susceptibility in Staphylococcus aureus in Boston, Massachusetts, from 2000 to 2014 publication-title: J Clin Microbiol doi: 10.1128/JCM.01160-17 – volume: 364 start-page: 1419 year: 2011 ident: 2020081004070240700_CIT0026 article-title: Veterans Affairs initiative to prevent methicillin-resistant Staphylococcus aureus infections publication-title: N Engl J Med doi: 10.1056/NEJMoa1007474 – volume: 37 start-page: 1288 year: 2016 ident: 2020081004070240700_CIT0005 article-title: Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014 publication-title: Infect Control Hosp Epidemiol doi: 10.1017/ice.2016.174 – volume: 35 start-page: 285 year: 2014 ident: 2020081004070240700_CIT0011 article-title: Continued emergence of USA300 methicillin-resistant Staphylococcus aureus in the United States: results from a nationwide surveillance study publication-title: Infect Control Hosp Epidemiol doi: 10.1086/675283 – volume: 69 start-page: 280 year: 2014 ident: 2020081004070240700_CIT0032 article-title: Resurgence of penicillin-susceptible Staphylococcus aureus at a hospital in New York State, USA publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkt317 – volume: 6 start-page: 213 year: 2000 ident: 2020081004070240700_CIT0009 article-title: Genetic relatedness of multidrug-resistant, methicillin (oxacillin)-resistant Staphylococcus aureus bloodstream isolates from SENTRY Antimicrobial Resistance Surveillance Centers worldwide, 1998 publication-title: Microb Drug Resist doi: 10.1089/mdr.2000.6.213 – volume: 301 start-page: 727 year: 2009 ident: 2020081004070240700_CIT0021 article-title: Methicillin-resistant Staphylococcus aureus central line-associated bloodstream infections in US intensive care units, 1997-2007 publication-title: JAMA doi: 10.1001/jama.2009.153 – volume: 52 start-page: 195 year: 2018 ident: 2020081004070240700_CIT0027 article-title: The impact of antibiotic prescription rates on the incidence of MRSA bloodstream infections: A county-level, US-wide analysis. publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2018.04.003 – volume: 24 start-page: 97 year: 2018 ident: 2020081004070240700_CIT0014 article-title: Evaluation of vancomycin MIC creep in methicillin-resistant Staphylococcus aureus infections-a systematic review and meta-analysis publication-title: Clin Microbiol Infect doi: 10.1016/j.cmi.2017.06.017 – volume: 32 start-page: S114 issue: Suppl 2 year: 2001 ident: 2020081004070240700_CIT0024 article-title: Survey of infections due to Staphyococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997–1999 publication-title: Clin Infect Dis doi: 10.1086/320184 – volume-title: Performance Standards for Antimicrobial Susceptibility Testing: 28th Informational Supplement year: 2018 ident: 2020081004070240700_CIT0020 – volume: 52 start-page: 3315 year: 2008 ident: 2020081004070240700_CIT0013 article-title: Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00113-08 – volume: 67 start-page: 802 year: 2012 ident: 2020081004070240700_CIT0025 article-title: Mandatory surveillance of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in England: the first 10 years publication-title: J Antimicrob Chemother doi: 10.1093/jac/dkr561 – volume: 304 start-page: 641 year: 2010 ident: 2020081004070240700_CIT0023 article-title: Health care-associated invasive MRSA infections, 2005-2008 publication-title: JAMA doi: 10.1001/jama.2010.1115 – volume: 129 start-page: 1331 year: 2016 ident: 2020081004070240700_CIT0031 article-title: Back to the future: penicillin-susceptible Staphylococcus aureus publication-title: Am J Med doi: 10.1016/j.amjmed.2016.01.048 – volume: 298 start-page: 1763 year: 2007 ident: 2020081004070240700_CIT0002 article-title: Invasive methicillin-resistant Staphylococcus aureus infections in the United States publication-title: JAMA doi: 10.1001/jama.298.15.1763 – volume: 50 start-page: 52 year: 2018 ident: 2020081004070240700_CIT0033 article-title: Trends in incidence and resistance patterns of Staphylococcus aureus bacteremia publication-title: Infect Dis doi: 10.1080/23744235.2017.1405276 – volume: 7 start-page: 629 year: 2009 ident: 2020081004070240700_CIT0001 article-title: Waves of resistance: Staphylococcus aureus in the antibiotic era publication-title: Nat Rev Microbiol doi: 10.1038/nrmicro2200 – volume: 14 start-page: 385 year: 1961 ident: 2020081004070240700_CIT0006 article-title: Methicillin-resistant staphylococci publication-title: J Clin Pathol doi: 10.1136/jcp.14.4.385 – volume: 52 start-page: e18 year: 2011 ident: 2020081004070240700_CIT0029 article-title: Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children publication-title: Clin Infect Dis doi: 10.1093/cid/ciq146 – reference: 31139676 - Open Forum Infect Dis. 2019 May 20;6(5):ofz202 |
| SSID | ssj0001105079 |
| Score | 2.518524 |
| Snippet | Abstract
Background
Staphylococcus aureus is among the most common human pathogens, with therapy complicated by the epidemic spread of methicillin-resistant... is among the most common human pathogens, with therapy complicated by the epidemic spread of methicillin-resistant (MRSA). The SENTRY Antimicrobial... Background Staphylococcus aureus is among the most common human pathogens, with therapy complicated by the epidemic spread of methicillin-resistant... Staphylococcus aureus is among the most common human pathogens, with therapy complicated by the epidemic spread of methicillin-resistant Staphylococcus aureus... |
| SourceID | pubmedcentral proquest pubmed crossref oup |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | S47 |
| SubjectTerms | Staphylococcus infections Supplement Surveillance |
| Title | Twenty-Year Trends in Antimicrobial Susceptibilities Among Staphylococcus aureus From the SENTRY Antimicrobial Surveillance Program |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30895214 https://www.proquest.com/docview/3170947520 https://www.proquest.com/docview/2195256057 https://pubmed.ncbi.nlm.nih.gov/PMC6419894 |
| Volume | 6 |
| WOSCitedRecordID | wos000510176800006&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2328-8957 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: DOA dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2328-8957 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: M~E dateStart: 20140101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVASL databaseName: Oxford Journals Open Access Collection customDbUrl: eissn: 2328-8957 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: TOX dateStart: 20140101 isFulltext: true titleUrlDefault: https://academic.oup.com/journals/ providerName: Oxford University Press – providerCode: PRVPQU databaseName: AUTh Library subscriptions: ProQuest Central customDbUrl: eissn: 2328-8957 dateEnd: 20241206 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: BENPR dateStart: 20140401 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2328-8957 dateEnd: 20241206 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: 7X7 dateStart: 20140401 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 2328-8957 dateEnd: 20241206 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: 8C1 dateStart: 20140401 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2328-8957 dateEnd: 20241206 omitProxy: false ssIdentifier: ssj0001105079 issn: 2328-8957 databaseCode: PIMPY dateStart: 20140401 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RFiEuvB-BshipJ6SoeTixc0JLtSs4dInaRdo9RfFLRKJJSTZFPfPHGSfZ7S6gXlAkR5ad2NKMPTOe8XwAR8Yz1ERUucYCAdJE5q6gsXYV96z4ljxUpgObYLMZXyySdDhwa4awyvWe2G3UqpL2jPwY5RxaIiwKvA-XP1yLGmW9qwOExh4c-IFH7cLkJ_7NGQsqDx5Lhmt5aLsfI8EUFteBBSfeEkQ7l9u2dMw_QyW3ZM_04f_O-hE8GLROMu7Z5DHc0eUTuHc6-NWfwq_5Txz52l0i35M-TJYUJRmXq-Ki6FI14dfnbdPFwHThtGhgk7EFKiKoriKpUCZWUrYNydta42taVxcElUtyPpnNz5Z__aq-0hbvCFmOpH2I2DP4Op3MTz65AzyDKyMvXmGpBefSFzw0qFb6WoXGGMbQ4pKShSo2SmgWGcN1nhuWBCZSNBH4GCmkEOFz2C-rUr8EEnAjmdJoTbGYmjARPJExjxJjqIqEHzjwfk2rTA65yy2Exves96GHmSVs1hPWgaNN58s-Zce_u71Fot_e43BN1GxY2U12Q1EH3m2acU1aR0te6qptMpQCkVUlI-bAi55_NuOEHsdGnzrAdjhr08Hm-95tKYtvXd7vmNoAN_rq9mm9hvuo1CV9nNwh7K_qVr-Bu_JqVTT1CPbYgnUlH3WLZQQHHyez9GzUnUZgLf18mi6xNv-y-A2lNimm |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFH4qBQEX9iVQqJHKBSlqJpvtA0Ij6KhV21FFB2l6CvEmItGkJJNWc-b_8Bt5zjKdAdRbDyiSc7DjbJ_fe04-vw9gy3gmNFGoXGOFAEMuU1eEsXYV86z7lixQphGboOMxm0750Rr86tfCWFplbxMbQ60Kab-Rb6Ofw5kIjXzvw9kP16pG2b-rvYRGC4t9Pb_AKVv1fu8Tvt-3vj_amXzcdTtVAVdGXjzDUgvG5ECwwGA0NNAqMMZQihMFKWmgYqOEppExTKepodw3kQq5wM1IIYUIsN8bcBPtOLUUMjqll990MFjxKO-WAXo82EaAKCzmvhVDXnJ8K4vplmLaP6mZS75udP9_e0oP4F4XVZNhOwwewprOH8Htw4438Bh-Ti7wTufuCV4aaWnAJMvJMJ9lp1mTigqPPq6rhuPT0IUzXZGhFWIiGI4jFNHnF1LWFUnrUuNuVBanBINncrwznnw--aur8lxbPSccUuSopcA9gS_X8giewnpe5Po5EJ8ZSZXG2SKNQxNwwbiMWcSNCVUkBr4D73psJLLLzW4lQr4nLUcgSCyQkhZIDmwtGp-1KUn-3WwTQXZ1i40eRElnuarkEkEOvFlUo82xP5LSXBd1laCXi2yoHFEHnrV4XZwn8BhWDkIH6AqSFw1sPvPVmjz71uQ1j0NL4AtfXH1Zm3Bnd3J4kBzsjfdfwl0MYHnLCdyA9VlZ61dwS57Psqp83QxOAl-vG-e_AbRIhWw |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Twenty-Year+Trends+in+Antimicrobial+Susceptibilities+Among+Staphylococcus+aureus+From+the+SENTRY+Antimicrobial+Surveillance+Program&rft.jtitle=Open+forum+infectious+diseases&rft.au=Diekema%2C+Daniel+J&rft.au=Pfaller%2C+Michael+A&rft.au=Shortridge%2C+Dee&rft.au=Zervos%2C+Marcos&rft.date=2019-03-01&rft.pub=Oxford+University+Press&rft.eissn=2328-8957&rft.volume=6&rft.issue=Supplement_1&rft.spage=S47&rft.epage=S53&rft_id=info:doi/10.1093%2Fofid%2Fofy270&rft.externalDocID=10.1093%2Fofid%2Fofy270 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2328-8957&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2328-8957&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2328-8957&client=summon |